Curis Lifesciences share price
NSE: CURISPharmaceuticals & Biotechnology
Curis Lifesciences Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2025 · Issue price ₹128
Last close ₹181.50up ₹1.50 (0.83%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹180.00.
28 Oct: open ₹182.00, high ₹182.00, low ₹181.00
Range of traded prices from listing on 14 Nov 2025 to 28 Oct 2026
₹83.60Low, 23 Mar 2026₹234.75High, 28 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹147 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.22
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.10
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Nov 2025
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 14.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.46
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,000100.0% delivered
Results
Standalone; ₹ crore.Curis Lifesciences half-yearly results
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹33 Crup 17.24%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹2.71 Crdown 35.75%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 8.3%
Revenue by half year
Peak revenue ₹33 Cr, half year to Mar 2026; lowest ₹28 Cr, half year to Sep 2025
Net profit by half year, a loss in red
| ₹ crore | Sep 2025 | Mar 2026 |
|---|---|---|
| Revenue | 27.9 | 32.7 |
| Net profit | 4.2 | 2.7 |
| Net margin | 15.1% | 8.3% |
Standalone. The 2 half years from Sep 2025, the first on record. The latest is shaded.
Year to Mar 2026
- Revenue
- ₹61 Cr
- Net profit
- ₹6.92 Cr
- Net margin
- 11.4%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 60.6 |
| Net profit | 6.9 |
| Net margin | 11.4% |
Standalone. Years to March.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturing of Pharmaceutical Products, which carries all its revenue.
Curis Lifesciences competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Curis Lifesciences in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Gujarat Inject (Kerala)GUJINJEC | 164 | 54.73 | 13.84 | +151.6% | +209.0% | 27.4% | 32.9% | 0.00% |
 Asston PharmaceuticalsAPL | 160 | 308.99 | – | – | – | 1.3% | −2.0% | 0.00% |
 Medico RemediesMEDICO | 159 | 11.54 | 2.11 | +50.0% | +33.7% | 20.1% | 15.3% | 0.00% |
 Smruthi OrganicsSMRUTHIORG | 156 | 21.04 | 2.12 | −4.6% | +118.2% | 10.2% | 14.8% | 1.10% |
 Kimia BiosciencesKIMIABL | 143 | 19.92 | 8.08 | −6.7% | −18.2% | 51.9% | 19.1% | 0.00% |
 Auro LaboratoriesAUROLAB | 143 | 30.53 | 3.08 | +125.5% | – | 10.5% | 8.8% | 0.00% |
 Natural CapsulesNATCAPSUQ | 142 | – | 0.64 | +8.8% | – | −9.5% | −5.2% | 0.00% |
 Par Drugs and ChemicalsPAR | 141 | 9.76 | 1.26 | +4.3% | +2.4% | 13.7% | 14.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Curis Lifesciences announcements
Sep 2026
7 Sep · Board meeting
3 Sep · Management
Curis Lifesciences share price by year
Each calendar year to 2025.Curis Lifesciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 120.60 | – | 141.00 | 108.90 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 14 Nov 2025.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 170.00 | 183.40 | 170.00 | 180.00 | 179.18 | 7,000 | 71.4% |
| 23 Oct 2026 | 178.10 | 178.10 | 176.45 | 176.45 | 177.01 | 4,000 | 100.0% |
| 22 Oct 2026 | 185.00 | 185.00 | 185.00 | 185.00 | 185.00 | 1,000 | 100.0% |
| 21 Oct 2026 | 185.90 | 187.00 | 180.65 | 185.00 | 184.68 | 6,000 | 83.3% |
| 19 Oct 2026 | 190.00 | 190.10 | 190.00 | 190.10 | 190.05 | 2,000 | 100.0% |
| 15 Oct 2026 | 193.00 | 199.70 | 193.00 | 199.00 | 197.23 | 3,000 | 100.0% |
| 14 Oct 2026 | 185.95 | 191.70 | 185.95 | 190.75 | 188.54 | 6,000 | 100.0% |
| 13 Oct 2026 | 182.35 | 184.00 | 182.35 | 182.60 | 182.84 | 9,000 | 88.9% |
| 12 Oct 2026 | 191.90 | 193.90 | 191.90 | 191.90 | 192.23 | 17,000 | 76.5% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- CURIS
- ISIN
- INE1BZN01016
- Industry
- Pharmaceuticals & Biotechnology